

# Cerebral and cardiac signal monitoring in fetal sheep with hypoxic-ischemic encephalopathy

Citation for published version (APA):

Zwanenburg, A. A. (2015). *Cerebral and cardiac signal monitoring in fetal sheep with hypoxic-ischemic encephalopathy*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20151119az>

## Document status and date:

Published: 01/01/2015

## DOI:

[10.26481/dis.20151119az](https://doi.org/10.26481/dis.20151119az)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.



Valorisation addendum



## VALORISATION ADDENDUM

Valorisation refers to the process of how academic research can be utilized and translated to clinical and societal benefit. The relevance of the research presented in this thesis is described in the section below.

### Part I: epidemiology of spondyloarthritis

Quantification of the burden of rheumatic conditions is important for raising awareness among health care professionals, setting research priorities and initiating a policy debate.[1] Rheumatic conditions have major impact on the individual patient, but also on society. Also in the case of spondyloarthritis (SpA), important decreases in almost all aspects of health related quality of life are reported. The onset at a relatively young age, before the fourth decade, adds to the years lived in disability for an individual.[2] As a consequence of decreased functioning, SpA has an adverse impact on the patient and family by reduced participation in social roles.[3,4] The indirect costs related to SpA are four times as high as the direct costs, reflecting the important impact of the disease on work participation in terms of sick leave, disability pensions and early retirement.[5] To extrapolate how this individual burden would affect society, appropriate data on the epidemiology are warranted. In this thesis, we found that the global prevalence of SpA was 0.55% (95% Confidence Interval (CI): 0.37-0.77). This prevalence is comparable to that of rheumatoid arthritis. Substantial variation across geographic regions was however found. For instance, the prevalence of SpA in East Asia was 0.79% (CI: 0.48-1.18). The study described in this thesis adds to the available evidence on epidemiology of rheumatic diseases that can contribute to prioritize research, but also to inform health care systems at the country level, when allocating budgets to improve diagnosis, treatment and prevention of work disability.[1,6-8]

### Part II: the use of MRI in early detection of axial spondyloarthritis

The introduction of MRI for detecting active sacroiliitis has revolutionized the diagnosis of axial SpA (axSpA), making an early diagnosis possible. This thesis showed that a positive MRI is a reliable finding: a positive MRI at baseline was strongly associated with a positive MRI of the sacroiliac joints (MRI-SIJ) over time, particularly in HLA-B27 positive patients. This is important for clinicians, because it suggests that a diagnosis of axSpA incorporating a positive MRI is robust and credible. Furthermore, the post-gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) MRI sequence can be safely omitted, which increases the feasibility of MRI, since it saves time and reduces costs.

Further, in axSpA it is a challenge to identify the appropriate target for treatment: should it be disease activity, prevention or delay in progression of structural damage, or both? In this thesis, we focused on the relation between inflammation and development of structural damage (erosions and fatty lesions) on MRI. We have shown that fatty lesions on MRI-SIJ preferably develop after bone marrow edema (BME) has subsided. Other studies have suggested that fatty lesions at vertebral edges predict the development of new syndesmophytes.[9] BME may therefore be the first domino that sets off the chain that leads to development of fatty lesions and eventually new bone formation (syndesmophytes).[10,11] The true relation between BME and new bone formation still needs to be disentangled in further research. This thesis has contributed in one of the many steps to unravel the relation between inflammation and structural damage on MRI in order to enable identification of different treatment targets.

### **Part III: early identification of spondyloarthritis in primary care**

Musculoskeletal disorders (MSD) are among the most common reasons for consulting a GP and have a major impact on healthcare resources.[12] The Global Burden of Disease 2010 study found that MSD, including rheumatic disorders, were the second main contributor to the number of years lived with disability.[1] Part of this burden is avoidable. The importance of MSD as major cause of (avoidable) disability, however, seems insufficiently acknowledged by GPs.[13,14] Training in rheumatology is rarely mandatory in general practice training programs, despite the large number of patients that present themselves in primary care with rheumatic disorders.[15] Nonetheless, it seems that musculoskeletal conditions are not a priority in primary care.[16,17]

Making a diagnosis of axSpA is often delayed up to 10 years or longer, suggesting that opportunities for early recognition and referral have been missed in primary care.[18,19] Several referral strategies that promote early referral of axSpA have been developed, but successful implementation may be hampered by ineffective referral patterns due to lack of knowledge about axSpA.[20-23] From this thesis, we learned that there is room for improvement with regard to the level of knowledge of GPs about their ability to identify and refer patients with suspected axSpA. Changing clinical practice behavior and assessing such change is a real challenge. The evidence that educational interventions may actually change anything is limited.[24] Lack of time and resources often contribute to failure of the education intervention.[24] This thesis shows that the use of standardized patients (SPs), is a feasible and informative approach to assess the impact of an educational intervention. More importantly, a multi-faceted educational program can play a key role in improving disease recognition

and referral of patients suspected for SpA. This important finding may further improve timely diagnosis and initiation of treatment of patients with SpA.

## REFERENCES

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2163-96.
2. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:61-6.
3. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. *J Rheumatol* 2006;78:4-11.
4. Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. *Nat Clin Pract Rheumatol* 2006;2:546-53.
5. Akesson K, Dreinhöfer KE, Woolf AD. Improved education in musculoskeletal conditions is necessary for all doctors. *Bull World Health Organ* 2003;81:677-83.
6. Badley EM, Rasooly I, Webster GK. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey. *J Rheumatol* 1994;21:505-14.
7. March L, Smith EU, Hoy DG, et al. Burden of disability due to musculoskeletal (MSK) disorders. *Best Pract Res Clin Rheumatol* 2014;28:353-366.
8. Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73:968-74.
9. Chiowchanwisawakit P, Lambert RG, Conner-Spady B, et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. *Arthritis Rheum* 2011;63:2215-25.
10. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. *Arthritis Rheum* 2009;60:93-102.
11. Song IH, Hermann KG, Haibel H, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. *Ann Rheum Dis* 2011;70:1257-63.
12. Jordan KP, Kadam UT, Hayward R, et al. Annual consultation prevalence of regional musculoskeletal problems in primary care: an observational study. *BMC Musculoskelet Disord* 2010;11:144.
13. Woolf AD, Akesson K. Understanding the burden of musculoskeletal conditions. The burden is huge and not reflected in national health priorities. *BMJ* 2001;322:1079-80.
14. Woolf AD, Akesson K. Can we reduce the burden of musculoskeletal conditions? The European action towards better musculoskeletal health. *Best Pract Res Clin Rheumatol* 2007;21:1-3.
15. Rasker JJ. Rheumatology in general practice. *Br J Rheumatol* 1995;34:494-7.
16. Hosie GA. Teaching rheumatology in primary care. *Ann Rheum Dis* 2000;59:500-3.
17. Lanyon P, Pope D, Croft P. Rheumatology education and management skills in general practice: a national study of trainees. *Ann Rheum Dis* 1995;54:735-9.
18. Jois RN, Macgregor AJ, Gaffney K. Recognition of inflammatory back pain and ankylosing spondylitis in primary care. *Rheumatology (Oxford)* 2008;47:1364-6.
19. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:61-6.
20. Poddubnyy D, Vahldiek J, Spiller I, et al. Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. *J Rheumatol* 2011;38:2452-60.
21. Brandt HC, Spiller I, Song IH, et al. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. *Ann Rheum Dis* 2007;66:1479-84.
22. Hermann J, Giessauf H, Schaffler G, et al. Early spondyloarthritis: usefulness of clinical screening. *Rheumatology (Oxford)* 2009;48:812-6.
23. Sieper J, Srinivasan S, Zamani O, et al. Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. *Ann Rheum Dis* 2013;72:1621-7.
24. Grol R, Wensing M. What drives change? Barriers to and incentives for achieving evidence-based practice. *Med J Aust* 2004;180:S57-60.